Editor’s note: This is an automatically generated transcript Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So I think the most important one is the ...
The treatment of Helicobacter pylori (H. pylori) infection remains a challenge due to the increasing prevalence of drug-resistant bacteria. It is hypothesized that using more potent acid suppressants, ...
Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study. This is an ASCO Meeting Abstract from the 2023 ...
Tegoprazan is superior to the proton pump inhibitor lansoprazole for healing erosive esophagitis as early as week 2, but one ...
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA ...
The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 ...
Credit: Phathom Pharmaceuticals. Voquezna, a potassium-competitive acid blocker, is supplied as 10mg and 20mg tablets. Voquezna ® (vonoprazan) is now available for the treatment of erosive esophagitis ...
Add Yahoo as a preferred source to see more of our stories on Google. Heartburn after meals? You’re not alone — acid reflux is on the rise, with one in five UK adults affected If you’ve ever reached ...
Phathom Pharmaceuticals launched its first broadcast direct-to-consumer (DTC) campaign to promote Voquezna, its treatment for all severities of erosive gastroesophageal reflux disease (GERD), ...
The FDA approved vonoprazan (Voquezna) for all grades of erosive gastroesophageal reflux disease (GERD) and heartburn relief associated with the condition, Phathom Pharmaceuticals announced on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results